What's Next in PV

NextPV Services, s.r.o.

Podcast that will take your drug safety to the #NextLevel. Pharmacovigilance is a complex science, but it should not be complicated. We at NextPV want to bring you insights and knowledge through our conversations. We will cover everything from big strategic topics to smaller operational ones and current news. Welcome and enjoy listening.

Puntate

  1. 2 H FA

    E2: PV Audit Readiness 2026 - Types of Audits, Gap Analysis, and Your Inspection Survival Guide

    In Episode 2 of What's Next in PV, Tereza Korecka sits down with Vojtech Kvita and Josue Vazquez from NextPV Services to break down exactly what audit readiness looks like in 2026 - under the expanded requirements of EU Regulation 2025/1466 and heightened regulatory expectations worldwide. It's a practitioner-to-practitioner conversation on what actually works, what adds real value, and what you can accomplish even when timelines are tight. Whether you're building your first audit program, preparing for an imminent inspection, or trying to demonstrate the strategic value of auditing to leadership, this episode delivers the clarity and action steps you need. (0:05) - Episode opening and introductions (0:28) - What is a PV audit? Differentiating between audits and inspections (0:38) - Vojtech begins explaining the fundamental differences between audits and inspections (2:32) - Discussion on regulatory authority inspections (EMA, FDA) (5:12) - Josue adds perspective on audits being about effectiveness, not just compliance (6:06) - Tereza transitions to EU Regulation 2025/1466 and its impact on auditing (6:41) - Vojtech explains how the regulation formalizes existing audit practices (10:14) - Josue confirms regulation doesn't fundamentally change how audits are performed (11:47) - Vojtech discusses practical contract implications under the new regulation (14:43) - Tereza summarizes: audits are meant to make life easier, not harder (14:52) - Vojtech's perspective from both sides of the audit table (16:30) - Shifting mindset: audits as opportunities, not threats (16:36) - Josue addresses the fear of findings and why audits shouldn't be feared (17:11) - Vojtech compares inspections to "the boogeyman" in PV (17:24) - The healthy nervousness analogy: inspections like university exams (18:23) - The six types of PV audits: Tereza asks about different audit types and when to use them (18:50) - Vojtech explains the audit universe: system audits, process audits, and organizational structure (22:39) - Josue discusses when to conduct different audit types based on MAH lifecycle (27:20) - For-cause audits explained: triggered by findings or deviations (30:29) - Gap analysis vs audit: what's the difference and how to use each? (30:50) - Vojtech defines gap analysis as a flexible, less formal assessment tool (33:35) - Vojtech continues: gap analysis enables more open conversations than formal audits (36:00) - Josue emphasizes both processes are for improvement, with different approaches (39:07) - Practical scenario: 6 months to first PV inspection with no audit prep - are they in trouble? (39:30) - Vojtech's reality check: you're not in trouble, but prioritization is key (43:48) - Vojtech on reinspection preparation: checking CAPA status from previous inspections (44:08) - Josue introduces mock inspections as a critical preparation tool (46:48) - Vojtech's final advice: don't fear audits, maintain your system, expect findings (49:58) - Discussion on not forcing findings when companies are compliant (50:52) - Josue's auditing philosophy: human approach, open communication, respectful evaluation (53:44) - Vojtech shares an inspection anecdote about inspector credentials and unnecessary gotcha moments (55:10) - Josue's example about language-based findings that don't serve improvement purposes (57:26) - Tereza's closing remarks and thank you Hosted by Tereza Korecka | Co-hosts: Vojtech Kvita and Josue Vazquez, NextPV Services Keywords: pharmacovigilance, PV audit, audit readiness, EU Regulation 2025/1466, gap analysis, inspection preparation, QPPV, MAH compliance, vendor oversight, PV quality management, GVP, drug safety, pharmaceutical auditing, system audit, process audit, third-party oversight

    57 min
  2. 10 FEB

    E1: PV Regulation 2025-2026: What Changed, What's Coming, and What You Must Do Now

    In this episode of What's Next in PV, co-founders Jan and Vojtech sit downto break down exactly what EU Regulation 2025/1466 means for marketingauthorization holders, biotech companies, and PV professionals navigating the2025-2026 regulatory wave. Key topics covered: - Signal management overhaul: Why standalone signal notifications have been eliminated, and what "EudraVigilance monitoring in parallel" actually requires - EVDAS mandate: The end of the pilot program, how to decide at which stage of your signal management processto use EVDAS, and why the reference period timing matters - Third-party auditing requirements: New subcontracting rules, contract clauses that now need updating, and how audit scope has expanded - GVP module revision wave: Which modules are being updated in Q1-Q4 2026 - Inspection readiness: Practical steps to take now, whether your organization is small and agile or large and complex   TIMESTAMPS: (00:00) - Intro and episode overview (00:46) - Why 2025-2026 is a pivotal moment for PV regulation (context setting) (01:13) - EU Regulation 2025/1466: The first major overhaul since 2012 (02:25) - Topic 1: Signal management - what has changed and why it matters (03:22) - History of EudraVigilance and the EVDAS pilot program (2017-2025) (05:22) - End of the EVDAS pilot: what mandatory "monitoring in parallel" actually means (06:09) - How MAHs can decide at which stage of signal management to use EVDAS(07:30) - Risk assessment before deciding your EVDAS strategy(08:03) - Why standalone signal notifications were eliminated(09:07) - Practical implications: how signals are now communicated to authorities(11:13) - PSUR vs. non-PSUR holders: who is affected and how(12:53) - Monitoring PRAC and meeting minutes as part of your signal management(14:08) - Why MAH and regulator EVDAS views differ - and what this means in practice (15:36) - EVDAS deep dive: ERMR, line listings, and the three core functionalities (17:26) - Reference periods explained: 15-day, 1-month, 3-month, 6-month, 1-year (19:07) - The fixed period trap: why you cannot run EVDAS retrospectively (21:08) - How to determine the right monitoring frequency for your portfolio (22:11) - Topic 2: Third-party and auditing - new requirements under Regulation2025/1466 (22:36) - Subcontracting rules: MAH consent now required for further delegation (23:45) - Practical contract guidance: MSA vs. SOW - where to include new clauses(24:55) - All subcontracted PV activities must now be included in audits (25:21) - A candid conversation: are audits always adding value? (27:09) - How to run audits that find real risk, not just checkbox findings (28:14) - What good audit strategy actually looks like (30:40) - Topic 3: GVP module updates coming in 2026 - the full picture (31:18) - GVP Module 9 (Signal Management): what to expect and when (32:06) - GVP Modules 5, 6, and addendums: scope of changes (33:22) - How organizations of different sizes should manage the update wave (35:17) - Should companies wait for Module 9 before updating SOPs? (36:01) - Deviation-based approach vs. full SOP update - which is right for your org?(38:14) - Practical implementation: memos to file, signal detection plans, and interim steps (39:12) - The "no less frequent than 6 months" clause being removed from Module 9(40:03) - Topic 4: What companies should do to be inspection-ready right now(40:18) - The two implementation deadlines: August 12, 2025 and February 12, 2026(41:40) - PSMF updates: deviations, wording changes, and what to check in your templates(42:11) - A message for overwhelmed teams: how to start when everything feels urgent(43:42) - Closing thoughts from Jan: planning for the wave of changes ahead(44:44) - Note on non-EU organizations: why context matters when communicating changes internally(45:14) - Closing thoughts from Vojtech: SOP interdependency and getting it right the first time(47:07) - Sign-off and next episode preview

    47 min

Descrizione

Podcast that will take your drug safety to the #NextLevel. Pharmacovigilance is a complex science, but it should not be complicated. We at NextPV want to bring you insights and knowledge through our conversations. We will cover everything from big strategic topics to smaller operational ones and current news. Welcome and enjoy listening.